- Home
- CCCC
CCCC
C4 Therapeutics Inc.
as 02-21-2025 4:00pm EST
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 244.9M | IPO Year: | 2020 |
| Target Price: | $11.60 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.79 - $11.88 | Next Earning Date: | 03-04-2025 |
| Revenue: | $33,668,000 | Revenue Growth: | 65.45% |
| Revenue Growth (this year): | 75.59% | Revenue Growth (next year): | -50.56% |
Stock Insider Trading Activity of C4 Therapeutics Inc. (CCCC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boyle Scott N | CCCC | Chief Business Officer | Feb 13 '25 | Sell | $3.15 | 1,159 | $3,650.85 | 110,842 |
Latest C4 Therapeutics Inc. News
CCCC Breaking Stock News: Dive into CCCC Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
UBS Downgrades C4 Therapeutics to Neutral From Buy, Adjusts Price Target to $4 From $18
Simply Wall St.
a month ago
3 Penny Stocks On US Exchanges To Consider In January 2025
GlobeNewswire
a month ago
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
GlobeNewswire
a month ago
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Zacks
2 months ago
Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now
Insider Monkey
2 months ago
Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now?
MT Newswires
2 months ago
Wells Fargo Upgrades C4 Therapeutics to Overweight From Equalweight, Raises Price Target to $12 From $8
GlobeNewswire
2 months ago
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
Compare CCCC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CCCC C4 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.